weiming wang

Dr. weiming wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZLZheng Liu
Zheng Liu
WDWen-Ting Dong
Wen-Ting Dong
WWWen-Feng Wei
Wen-Feng Wei
JHJin Huo
Jin Huo
WWweiming wang
weiming wang

4 November 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ZLZheng Liu
Zheng Liu
JHJin-Hai Huo
Jin-Hai Huo
WDWen-Ting Dong
Wen-Ting Dong
GSGuo-Dong Sun
Guo-Dong Sun
FLFeng-Jin Li
Feng-Jin Li
WWweiming wang
weiming wang
Qinbaiqingfei concentrated pills (QB) are a commonly used medicine for the treatment of mycoplasma pneumonia in China, and the mechanism of action of QB needs to be studied further. Therefore, we use a combination of metabolomics and network pharmacology to clarify the mechanism of QB. Nontarget metabolomics studies were performed on rat serum, urine, and lung tissues, and 56 therapeutic biomarkers were found. Subsequently, the components of QB absorbed into the blood and lung tissues were clarified, and based on this finding, the core target of network pharmacology was predicted. The enrichment analysis of biomarkers–genes finally confirmed their close relationship with the NF-κB signaling pathway. By western blotting expression of the proteins in the lung tissue–related signaling pathways, it is finally confirmed that QB inhibits the NF-κB signaling pathway through SIRT1, IL-10 and MMP9, CTNNB1, EGFR, and other targets. It plays a role in regulating immunity, regulating metabolism, and treating diseases.